Kezar Life Sciences, Inc.: share-based compensation expense
Share-based compensation expense for Kezar Life Sciences, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Kezar Life Sciences, Inc. financial histories
What this measure means
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
Exact concept: us-gaap:ShareBasedCompensation. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2016-01-01 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2025-01-01 | 2025-12-31 | 8,963,000 | USD | 2026-03-27 | 10-K · 0001628280-26-021737 |
| 2024-01-01 | 2024-12-31 | 13,011,000 | USD | 2026-03-27 | 10-K · 0001628280-26-021737 |
| 2023-01-01 | 2023-12-31 | 18,137,000 | USD | 2026-03-27 | 10-K · 0001628280-26-021737 |
| 2022-01-01 | 2022-12-31 | 14,006,000 | USD | 2025-03-25 | 10-K · 0001645666-25-000010 |
| 2021-01-01 | 2021-12-31 | 7,596,000 | USD | 2024-03-14 | 10-K · 0000950170-24-031494 |
| 2020-01-01 | 2020-12-31 | 4,943,000 | USD | 2023-03-14 | 10-K · 0000950170-23-007871 |
| 2019-01-01 | 2019-12-31 | 4,007,000 | USD | 2022-03-17 | 10-K · 0000950170-22-004085 |
| 2018-01-01 | 2018-12-31 | 1,993,000 | USD | 2021-03-11 | 10-K · 0001564590-21-012525 |
| 2017-01-01 | 2017-12-31 | 203,000 | USD | 2020-03-12 | 10-K · 0001564590-20-010498 |
| 2016-01-01 | 2016-12-31 | 128,000 | USD | 2019-03-26 | 10-K · 0001564590-19-009369 |
Related financial histories
- Kezar Life Sciences, Inc.: total assets
- Kezar Life Sciences, Inc.: total liabilities
- Kezar Life Sciences, Inc.: stockholders equity
- Kezar Life Sciences, Inc.: cash and cash equivalents
- Kezar Life Sciences, Inc.: net income or loss
- Kezar Life Sciences, Inc.: operating cash flow
- Kezar Life Sciences, Inc.: capital expenditure payments
- Kezar Life Sciences, Inc.: contract revenue excluding tax
- Kezar Life Sciences, Inc.: financing cash flow
- Kezar Life Sciences, Inc.: investing cash flow
- Kezar Life Sciences, Inc.: retained earnings or deficit
- Kezar Life Sciences, Inc.: basic weighted-average shares
- Kezar Life Sciences, Inc.: diluted weighted-average shares
- Kezar Life Sciences, Inc.: basic earnings per share
- Kezar Life Sciences, Inc.: diluted earnings per share
- Kezar Life Sciences, Inc.: net property, plant and equipment
- Kezar Life Sciences, Inc.: operating income or loss
- Kezar Life Sciences, Inc.: current assets
- Kezar Life Sciences, Inc.: interest expense
- Kezar Life Sciences, Inc.: current liabilities
- Kezar Life Sciences, Inc.: current accounts payable
- Kezar Life Sciences, Inc.: operating expenses
- Kezar Life Sciences, Inc.: research and development expense
Inspect the source
- Entity
- Kezar Life Sciences, Inc. / CIK 0001645666
- Captured
- 2026-09-21T17:21:46.717Z
- SEC response SHA-256
ac70ddc9a9d6d5bfd5f62a628f707069f98d9f877f40e35453df7cf42ed18d6d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001645666.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))